62
Participants
Start Date
March 17, 2022
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
REC-994
REC-994 200 mg tablets
Placebo
Placebo Tablets
Columbia University Medical Center, New York
University of Rochester Medical Center, Rochester
University of Pittsburgh, Pittsburgh
Thomas Jefferson University, Philadelphia
University of Pennsylvania, Philadelphia
University of Virginia, Charlottesville
Emory, Atlanta
University of Florida, Gainesville
Cleveland Clinic Florida, Port Saint Lucie
Xenoscience Inc, Phoenix
UCLA, Los Angeles
Stanford University, Palo Alto
Lyerly Neurosurgery, Jacksonville
Valley Hospital, Ridgewood
The University of Texas Southwestern Medical Center, Dallas
Recursion Pharmaceuticals Inc.
INDUSTRY